Search

Displaying results 1691 - 1700 of 8412 in total
  1. Drug

    Foscarnet

    go.drugbank.com/drugs/DB00529
    ApprovedInvestigational

    An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.

  2. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination … being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)[L12675] with an

  3. Drug

    Arotinoid acid

    go.drugbank.com/drugs/DB02877
    Experimental

    Arotinoid acid is a retinoic acid analog which acts as a selective RAR agonist.

  4. Drug

    Iron protein succinylate

    go.drugbank.com/drugs/DB11209
    Approved

    Mixtures: Triveen-Duo DHA, PR Natal 430
  5. Drug

    AUTO3

    go.drugbank.com/drugs/DB17364
    Investigational

    It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.

  6. Drug

    KITE-585

    go.drugbank.com/drugs/DB17409
    Investigational

    KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.

  7. Drug

    AVR-RD-04

    go.drugbank.com/drugs/DB18644
    Experimental

    AVR-RD-04 is an investigational gene therapy for cystinosis.

  8. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … [L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399]

  9. Drug

    Lovastatin

    go.drugbank.com/drugs/DB00227
    ApprovedInvestigational

    [A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD … [A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsSynonyms: (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate
  10. Drug

    Influenza A virus A/Idaho/07/2018 (H1N1) antigen (MDCK cell derived, propiolactone inactivated

    go.drugbank.com/drugs/DB15505
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Flucelvax Quadrivalent (multi-dose Vial)